



SOUTHERN SYMPOSIUM ON FOREGUT CANCERS

CORK 2012

in conjunction with the



4TH SYMPOSIUM

THE MULTIMODALITY MANAGEMENT
OF COLORECTAL CANCER LIVER
METASTASES

DEVERE HALL, STUDENT CENTRE, UNIVERSITY COLLEGE CORK
FRIDAY 19TH / SATURDAY 20TH OCTOBER 2012

This conference has been accredited with 10.5 CPD points

CONTENT

Introduction to Guest Speakers	1
Friday Programme	2-3
Saturday Programme	3-5
Guest Speaker Bibliographies	6-13

The Organising Committee of the Southern Symposium on Foregut Cancers would like to acknowledge the support of the following industry sponsors:

Platinum Sponsor



Gold Sponsors



Silver Sponsors



Bronze Sponsors



GUEST SPEAKERS

- PROFESSOR MICHAEL I D'ANGELICA**
Department of Surgery, Hepatopancreaticobiliary Service, Memorial Sloan Kettering Cancer Centre, New York, USA

PROFESSOR AIMERY DE GRAMONT
Head of the Medical Oncology Service, Hopital Saint-Antoine, Paris, France

MR EMIR HOTI
Consultant Hepatopancreaticobiliary Surgeon, Department of Surgery, St Vincent's University Hospital, Dublin

MR DAVID JAYNE
Senior Lecturer, University of Leeds/Consultant Surgeon, Leeds Teaching Hospitals NHS Trust, UK

MR MYLES JOYCE
Consultant Surgeon, Galway University Hospital, Galway

PROFESSOR NANCY E KEMENY
Attending Medical Oncologist, Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Centre, New York, USA

DR GEOFF KU
Attending Medical Oncologist, Dept of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Centre, New York, USA

PROFESSOR DAVID C LINEHAN
Chief, Division of General Surgery, Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery, Washington University Cancer Centre, St. Louis, USA

PROFESSOR MARIA B MAJELLA DOYLE
Assistant Professor of Surgery and Director of the HPB Fellowship Program, Division of General Surgery, Section of Abdominal Transplantation, Washington University, St Louis, USA

DR JOHN L MARSHALL
Chief, Hematology and Oncology / Professor of Medicine and Oncology / Associate Director of Clinical Research / Director Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington

PROF DAVID SEBAG MONTEFIORE
Professor of Clinical Oncology, University of Leeds, UK

MR GARRETT NASH
Consultant Colorectal Surgeon, Memorial Sloan Kettering Cancer Centre, New York

DR BRIAN O'NEILL
Consultant Radiation Oncologist, St Luke's & Beaumont Hospital's, Dublin

DR KEVIN O'REGAN
Consultant Radiologist, Cork University Hospital, Cork

MR MÍCHEÁL Ó RÍORDÁIN
Consultant Colorectal Surgeon, Mercy University Hospital, Cork

DR DEREK POWER
Consultant Medical Oncologist, Mercy University Hospital, Cork

PROFESSOR GRAEME POSTON
Consultant Hepato-biliary Surgeon, University Hospital Aintree, Liverpool, & Professor of Surgery of the University of Liverpool, UK

PROFESSOR PHIL QUIRKE
Professor of Pathology, School of Medicine, University of Leeds, UK

PROFESSOR DUSHYANT V SAHANI
Director of CT, Associate Professor of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, USA

DR NEIL SEGAL
Attending Medical Oncologist, Dept of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Centre, New York, USA

DR RICHARD A SHARMA
Consultant Clinical Oncologist, Department of Radiation Oncology, University of Oxford, Churchill Hospital, Oxford, UK

THE MULTIMODALITY MANAGEMENT OF COLORECTAL CANCER LIVER METASTASES

13.30 Welcome Address and Opening
Dr Gregory Leonard, Consultant Medical Oncologist, Galway University Hospital
Dr Susan O Reilly, Director, National Cancer Control Programme

CONTROVERSIES IN COLORECTAL CANCER

SESSION 1: 13.45 – 15.45

Chairperson: Mr Emmet Andrews, Consultant Colorectal Surgeon, Cork University Hospital

13.45 Peritoneal Carcinomatosis: What is the Optimal Treatment?
The Surgery Perspective
Mr Garrett Nash, Consultant Colorectal Surgeon, Memorial Sloan Kettering Cancer Center, New York

14.15 What is Bad Prognosis Stage II Colon Cancer?
What Your Pathologist Can Tell You
Professor Phil Quirke, Professor of Pathology, School of Medicine, University of Leeds, UK

Chairperson: Prof Calvin Coffey, Consultant Surgeon, University Hospital Limerick
Mr Fiachra Cooke, Consultant Colorectal Surgeon, Waterford Regional Hospital

14.45 A DEBATE: 'T3 Rectal Cancer in the Era of TME: What is the Optimal Treatment?'
For: Prof David Sebag Montefiore, Professor of Clinical Oncology, University of Leeds, UK
Against: Mr Myles Joyce, Consultant Surgeon, Galway University Hospital, Galway

15.15 Short Course Radiotherapy VS Long Course Chemoradiotherapy for Rectal Cancer
Dr Brian O'Neill, Consultant Radiation Oncologist, St Luke's & Beaumont Hospitals, Dublin

15:45 Coffee Break

UPDATES IN THE SURGICAL MANAGEMENT OF COLORECTAL CANCER

SESSION 2: 16.15 – 18.45

Chairpersons: Ms Debbie McNamara, Consultant Surgeon, Beaumont Hospital
Mr David Waldron, Consultant Colorectal Surgeon, University Hospital Limerick

16.15 Laparoscopic Surgery for Colorectal Cancer
Mr Micheál Ó Ríordáin, Consultant Colorectal Surgeon, Mercy University Hospital, Cork

16.35 Robotic Surgery for Colorectal Cancer
Mr David Jayne, Senior Lecturer, University of Leeds/Consultant Surgeon, Leeds Teaching Hospitals NHS Trust, UK

Chairperson: Dr David Gallagher, Consultant Medical Oncologist, Mater Private Hospital, Dublin

17.00 Inherited Colorectal Cancer Syndromes - Who Should be Tested?
Dr Derek Power, Consultant Medical Oncologist, Mercy University Hospital, Cork

Chairperson: Dr Richard Wilson, Consultant Medical Oncologist, Belfast City Hospital

17.30 KEY NOTE SPEAKER
Managing Colon Cancer in the Era of Personalised Medicine
Dr John L Marshall, Chief, Hematology and Oncology / Professor of Medicine and Oncology / Associate Director of Clinical Research / Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington

18.30 Closing Remarks
Dr Gregory Leonard, Consultant Medical Oncologist, Galway University Hospital

18.45 Close

19.00 Wine Reception – Lewis Glucksmann Gallery, University College Cork

SATURDAY OCTOBER 20TH 2012

08:00 Registration

08.45 Welcome Address
Mr Criostoir O Suilleabhain Consultant Hepatobiliary Pancreatic Surgeon, Mercy University Hospital, Cork

09.00 An Overview
Improved Survival in Metastatic Colorectal Cancer is Associated with Adoption of Hepatic Resection and Chemotherapy
Professor Graeme Poston, Consultant Hepato-biliary Surgeon, University Hospital Aintree, Liverpool, & Professor of Surgery of the University of Liverpool, UK

IMAGING

SESSION 1: 09.30 - 10.45

Chairpersons: Dr Peter McEneaney, Consultant Radiologist, Mercy University Hospital, Cork
Dr Michael Moore, Consultant Radiologist, Cork University Hospital, Cork

09:30 The Role of Cross Sectional Imaging and Ultrasound in Liver Resection and Follow Up
Professor Dushyant V Sahani, Director of CT, Associate Professor of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, USA

10:00 Is Metabolic Imaging Prior to Liver Resection Necessary?
Dr Kevin O'Regan, Consultant Radiologist, Cork University Hospital, Cork

10:20 Q & A

10:30 Coffee Break

SURGERY

SESSION 2: 10.45 TO 12.30

Chairpersons: Mr Gerry McEntee, Consultant Hepatobiliary and Pancreatic Surgeon, Mater Misericordiae University Hospital, Dublin
Mr Adrian O'Sullivan, Consultant Hepatobiliary and Pancreatic Surgeon, Cork/Mercy University Hospitals, Cork

10.45 Definitions of Resectability and the Evolution of Surgical Strategies
Professor David C Linehan, Chief, Division of General Surgery, Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery, Washington University Cancer Centre, St. Louis, USA

11.15 Synchronous or Metachronous Resection of Liver Metastases and Primary Colorectal Cancer
Professor Maria B. Majella Doyle, Assistant Professor of Surgery and Director of the HPB Fellowship Program, Division of General Surgery, Section of Abdominal Transplantation, Washington University in St Louis

11.45 Resection of Extrahepatic Disease: Why and When?
Professor Michael I D'Angelica, Department of Surgery, Hepatopancreaticobiliary Service, Memorial Sloan Kettering Cancer Centre, New York, USA

12.15 Q & A

12:30 Lunch

SYSTEMIC CHEMOBIOLOGIC THERAPY

SESSION 3: 13.15 TO 15.00

Chairpersons: Dr Ray McDermott, Consultant Medical Oncologist, AMNCH Tallaght Hospital, Dublin
Professor Rajnish Gupta, Consultant Medical Oncologist, University Hospital Limerick

13.15 Anti-EGFR therapies: the more we know...
Dr Geoff Ku, Attending Medical Oncologist, Dept of Gastrointestinal Oncology Memorial Sloan Kettering Cancer Centre, New York, USA

13.45 Evolution of Systemic Therapy with a Focus on Anti-Angiogenic Strategies and Beyond
Dr Neil Segal, Attending Medical Oncologist, Dept of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Centre, New York, USA

14.15 New Paradigms for the Treatment of Metastatic Colorectal Cancer (MCRC)
Professor Aimery De Gramont, Head of the Medical Oncology Service, Hopital Saint-Antoine, Paris, France

14.45 Q & A

REGIONAL THERAPY

SESSION 4: 15.00 - 16.45

Chairperson: Dr Derek Power, Consultant Medical Oncologist, Mercy University Hospital, Cork
Dr David Tuite, Consultant Interventional Radiologist, Cork University Hospital, Cork
Dr Brian Bird, Consultant Medical Oncologist, Bons Secours Hospital, Cork

15.00 Hepatic Arterial Infusion in Liver Resection – State of the Art
Professor Nancy E Kemeny, Attending Medical Oncologist, Department of Medicine, Gastrointestinal Oncology, Service, Memorial Sloan Kettering Cancer Centre, New York, USA

15.30 Yttrium-Labeled Microspheres
Dr Richard A Sharma, Consultant Clinical Oncologist, Department of Radiation Oncology, University of Oxford, Churchill Hospital, Oxford, UK

16:00 Ablative Therapies
Mr Emir Hoti, Consultant Hepatopancreaticobiliary Surgeon, Department of Surgery, St Vincent's University Hospital, Dublin

16:30 Q & A

16:45 Coffee Break

INAUGURAL PROFESSOR GERRY O'SULLIVAN MEMORIAL LECTURE

SESSION 5: 17.00 - 17.45

Chairperson: Mr Criostóir Ó Súilleabháin, Consultant Hepatobiliary and Pancreatic Surgeon, Mercy University Hospital, Cork

Genetic and Molecular Analysis of Solid Tumors will Personalize Future Therapies
Keynote Speaker: Professor David C Linehan, Chief, Division of General Surgery, Section of Hepatobiliary-Pancreatic and Gastrointestinal, Washington University Cancer Centre, St. Louis, USA

MEET THE EXPERTS: PATIENT FORUM – (18:00-19:00)

20:30 Conference Dinner: Aula Maxima, University College Cork

GUEST SPEAKERS

Dr Michael D'Angelica



Dr Michael D'Angelica received his medical degree from Tufts University in 1993 and subsequently completed training in general surgery at the University of Connecticut in 2000. He has completed research and clinical fellowships in surgical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr D'Angelica is currently an associate attending surgeon at MSKCC on the Hepatopancreatobiliary service and an associate professor of surgery at Cornell University. His principal research interests are in the biology and treatment of hepatobiliary malignancy and has specific interests in biomarkers and clinical trial development. He has authored or co-authored over 200 peer-reviewed manuscripts, book chapters and reviews as well as lectured extensively throughout the world on this topic.

Professor Maria B Majella Doyle



Maria B Majella Doyle, M.D., F.A.C.S., is an Assistant Professor of Surgery and Director of the HPB Fellowship Program in the Division of General Surgery, Section of Abdominal Transplantation, at Washington University in St. Louis. Dr Maria Doyle received her Bachelor of Arts Degree at Trinity College in Dublin Ireland before completion of medical school at the Royal College of Surgeons in Ireland. She then completed her surgical residency in the Irish General Surgical Training Program at the Royal College of Surgeons before completing a Research Fellowship in the Department of Academic Surgery at Cork University in Cork, Ireland. She completed a Clinical Fellowship in Abdominal Organ Transplant and HBP surgery at Washington University School of Medicine in St. Louis, Missouri and was subsequently recruited as a member of the Abdominal Organ Transplant and Hepatobiliary Surgery team. Her interests at the university are focused on adult and pediatric hepatobiliary and pancreatic surgery as well as liver and kidney transplant. She focuses her clinical research interests on clinical outcomes, liver cancer and transplantation, and donor management.

Professor Aimery de Gramont



Professor Gramont has been head of the Medical Oncology Service at Hôpital Saint-Antoine in Paris, France since 2002 and Head of the Cancer Biology and Therapeutics Group at Université Pierre et Marie Curie since 2005. As President of GERCOR he has acted as principal investigator in several large phase III studies involving 6000 patients and more than 200 investigators, including the OPTIMOX studies, the MOSAIC study and the ongoing AVANT trial. Professor Gramont is a Scientific Committee meeting member of ESMO, a Faculty member of the ASCO as well as Co-Chair of the International Society of Gastrointestinal Oncology Scientific Board, and is a regular presenter at these meetings.

Mr Emir Hoti



Mr Emir Hoti is currently a consultant surgeon at Saint Vincent's University Hospital, Dublin. Previously Mr Hoti has worked as hepatobiliary surgeon at Centre Hepato-Biliare, Hopital Paul Brousse (Paris). His main fields of activity and research include Hepatobiliary/ Pancreatic and Liver Transplantation Surgery. He is particularly involved in the treatment of cholangiocarcinoma, hepatocellular carcinoma and colorectal liver metastases.

Professor David Jayne



Professor David Jayne qualified from the University of Wales College of Medicine in 1989. His surgical training has been in North West Deanery, The Yorkshire & Humber Deanery, and as overseas Colorectal Fellow at Singapore General Hospital. During this time he was Clinical Fellow for the MRC CLASSIC trial, investigating laparoscopic versus open surgery for colorectal cancer. In 2011, he was appointed Professor of Surgery at the University of Leeds. His clinical interests include laparoscopic and robotic surgery. He is Chair of the Research & Audit Committee and Executive Member to the Association of Coloproctology of Great Britain & Ireland. His research interests include the molecular biology of colorectal cancer (tumour metabolism and metastasis), new technologies for minimally invasive and robotic surgery, and intraoperative fluorescence for stratified colorectal cancer surgery. He is Chief Investigator on several NIHR portfolio studies, including MRC/EME/NIHR ROLARR trial (a pan-world trial evaluating robotic surgery for rectal cancer), NIHR/HTA/FIAT (collagen plug for fistula-in-ano), and MRC/EME/NIHR GliSTen (intraoperative fluorescence for stratified colon cancer surgery). In 2012, he was awarded an NIHR Research Professorship to develop new surgical technologies for minimally invasive surgery.

Mr Myles R Joyce



Mr Joyce is currently working as a General / Colorectal Surgeon in University College Hospital Galway. He is a Galway graduate (1997), completed the Western Surgical SHO scheme followed by an MD in Beaumont Hospital (2000). He completed higher surgical training in Ireland followed by a colorectal fellowship (2007) in the Cleveland Clinic, Ohio, USA. He then worked as a colorectal surgeon in the Cleveland Clinic before taking up position in Galway (2010). Mr Myles Joyce's main areas of colorectal interest include minimally invasive colorectal surgery, inflammatory bowel disease, ileal pouch surgery, complex gastrointestinal fistula surgery and surgery for restoration of intestinal continuity.

GUEST SPEAKERS

Dr Nancy Kemeny



Dr Kemeny is a medical oncologist with a special expertise in developing new chemotherapy regimens for colorectal cancer. During her 35 years at Memorial Sloan-Kettering, she conducted some of the first studies using drugs such as irinotecan and oxaliplatin, which are now widely used in patients with colorectal cancer. She was also the lead investigator of a large, multi-institutional study that helped in the Food and Drug Administration's approval of oxaliplatin for colorectal cancer treatment in the U.S. Dr Kemeny's research has involved improving the outcome for patients with liver metastases using regional chemotherapy. Regional chemotherapy involves administering drugs into an artery that feeds tumors in the liver. This can be done using an internally implanted pump. The effectiveness of regional chemotherapy given in combination with systemic chemotherapy has led to its use in patients with surgically resected (removed) liver metastases. This combination has decreased the recurrence of disease after liver resection. New studies using this therapy have allowed patients with extensive liver disease who are not eligible for resection to achieve an excellent response, which then allows resection. This treatment has also been used this treatment for patients with primary liver cancer. In addition to Dr Kemeny's clinical and research responsibilities at Memorial Sloan-Kettering, she is a professor of medicine at Weill Cornell Medical College.

Dr Geoff Ku



Dr Geoff Ku is a Medical Oncologist in Memorial Sloan Kettering Cancer Centre, New York. He specialises in the treatment of malignancies of the gastrointestinal tract, including esophageal, stomach, colorectal, and pancreatic cancers. My research focuses on the development of new treatments for patients with esophageal and gastric cancers.

Professor David C Linehan



David C. Linehan, M.D. is Professor of Surgery and Chief of the Section of Hepatobiliary, Pancreatic and Gastrointestinal Surgery at Washington University School of Medicine. Dr Linehan's clinical expertise is in the multi-modality treatment of hepatobiliary and pancreatic malignancies. Dr Linehan is the author of many basic science and clinical manuscripts and he directs a laboratory whose focus is on the tumor microenvirnment and the cell-mediated immune response to cancer. In addition, Dr Linehan is active in clinical investigation and serves as Principal Investigator on several, on-going multi-modality clinical trials at the Siteman Cancer Center.

Dr John L Marshall



Dr Marshall received his training at Duke University, the University of Louisville, and Georgetown University. Dr Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials. While he has an interest in many areas of cancer research, his primary focus has been on the development of vaccines to treat cancer. Dr Marshall has become an outspoken advocate for GI cancer patients and the importance of clinical research participation. Most recently, he has established the Otto J Ruesch Center for the Cure of GI Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy.

Mr Garrett Nash



Dr Garrett Nash received an MD from the College of Physicians and Surgeons of Columbia University, New York and an MPH in Epidemiology and Biostatistics from Harvard School of Public Health, Boston. He is an Assistant Professor of Surgery at Weill-Cornell Medical College and a Surgeon at Memorial Sloan-Kettering Cancer Center in New York. The focuses of his clinical practice include minimally invasive techniques for colorectal cancer and the management of peritoneal surface malignancies (including appendix cancer, pseudomyxoma peritonei and mesothelioma). His clinical research involves prospective clinical trials of new technology and surgical techniques for advanced colorectal and appendiceal malignancies, as well as optimizing surgical margins and lymph node retrieval for colon and rectal cancers. He is the primary investigator of the first American randomized trial of intraperitoneal chemotherapy for appendix and colon cancer; this trial is expected to begin enrolling patients in January 2013. He is from Newcastle West, Co. Limerick and attended Castleknock College, Dublin.

Dr Brian DP O'Neill



Dr Brian DP O'Neill is a Consultant Radiation Oncologist at St Luke's and Beaumont Hospitals, where his specialist interests are Gastrointestinal and Genitourinary Radiation Oncology. Dr O'Neill is the National Lead for GastroIntestinal Radiation Oncology and an Author of the National Cancer Control Programme clinical guidelines for upper and lower GastroIntestinal cancers. Dr O'Neill is the Chief Investigator of an Irish Cooperative Oncology Research Group (ICORG) randomised rectal cancer study, which will recruit almost 300 patients. This trial will investigate if a new Radiotherapy technology, 'RAPIDARC' can reduce bowel and bladder toxicity for patients undergoing preoperative chemoradiotherapy for rectal cancer. Dr O'Neill is a Radiotherapy Lead for an Irish Cooperative Oncology Research Group (ICORG) randomised oesophageal cancer study, which will recruit over 350 patients in Ireland and Europe. This trial will investigate the most appropriate preoperative therapy for adenocarcinoma of the oesophago-gastric junction.

GUEST SPEAKERS

Dr Kevin O'Regan



Dr Kevin O'Regan is a Consultant Radiologist in Cork University Hospital. He is also the Lead Clinician in PET/CT, and the lead Clinician in Prostate Cancer for CUH. He attended medical school in UCC, graduating in 2001, and obtained his postgraduate qualifications in both medicine and radiology in the Cork Teaching Hospitals. His qualifications are MB BCh BAO BMed Sci MRCPI FFRRCSI. He undertook a 2-year Fellowship at the Dana Farber Cancer Center, in Boston, MA, USA from 2009 – 2011, where he specialised in oncology imaging and PET/CT. His main research interests are PET/CT, dose reduction in CT, melanoma, and soft tissue sarcoma.

Mr Mícheál Ó'Ríordáin



Mr Mícheál Ó'Ríordáin is a Consultant Colorectal Surgeon in Mercy University Hospital, Cork and Senior Lecturer in surgery in University College Cork. He is a graduate of University College Cork and trained on the Irish Higher Surgical Training Scheme as well as the Royal Infirmary Edinburgh, Brigham & Women's Hospital, Boston and the Cleveland Clinic, Cleveland, Ohio. He currently is the President of the Irish Association of Coloproctology and is the lead clinician for rectal cancer in the Southern region. His main interest is minimally invasive surgery, particularly in relation to colorectal cancer.

Mr Graeme Poston



Graeme Poston is Consultant Hepato-biliary Surgeon at University Hospital Aintree, Liverpool, UK and Professor of Surgery of the University of Liverpool. He enjoys an international reputation in hepatobiliary surgery. To date, he has personally performed over 800 major hepatobiliary resections. His unit at UHA is one of the largest tertiary resectional hepato-biliary practices in the UK, having performed nearly 2,000 liver resections over the last 20 years. He gained his undergraduate medical training at St Georges Hospital Medical School, London, and postgraduate training at The Hammersmith Hospital and St Mary's Hospital, London and University of Texas Medical Branch, Galveston, Texas.

He is President of the European Society of Surgical Oncology, past-President of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and the British Association of Surgical Oncology. He is Chair of NHS HPB Specialised Commissioning, Chair of the NICE Colorectal Cancer Guideline Development Group and Quality Standards Committee, and past-Chair of the Cancer Services Committee of the Royal College of Surgeons of England. He is a principal investigator of a number of ongoing national and international clinical trials in hepato-biliary surgery, and co-author of numerous national and international guidelines for the management of Hepatobiliary cancers, nine textbooks of surgery, and over 170 papers.

Dr Derek Power



Derek Power graduated from Trinity College Dublin in 1994 with an honours degree in Pharmacy. He then graduated from the Royal College of Surgeons in Ireland in 2001 with an honours medical degree. After his general medical training and 2 years of specialist training in medical oncology he won a bursary from the Irish Society of Medical Oncology and embarked on a Solid Tumour fellowship in Memorial Sloan Kettering Cancer Centre, New York 2007-2009. He then did a Cancer Genetics fellowship in Memorial Sloan Kettering Cancer Centre 2009-2010. He was appointed as a Consultant Medical Oncologist in The Mercy and Cork University Hospitals – July 2010. Interests include melanoma, gastrointestinal and genitourinary cancers as well as familial cancer genetics. Dr Power has published original papers in the use of novel compounds in upper gastrointestinal cancer as well as reviews and book chapters in GI cancers. He has given oral presentations at the ASCO and ESMO meeting and is a member of national and international cancer organisations.

Professor Phil Quirke



He leads the section of pathology and tumour biology and has a major research interest in Bowel cancer, digital pathology and postgraduate education. Phil's major achievements have been: to identify the cause of local recurrence in rectal cancer and open up the way to minimise this occurrence; to show that simple observations of cancer surgery and the specimens that are removed by surgeons can identify the quality of the operating surgeon and that educational interventions using excellent surgeons can improve outcomes in a number of European countries; to show that the standard operation for low rectal cancer carries a high risk of leaving tumour behind and that a different type of operation the extra levator abdomino–perineal excision can greatly reduce this risk; that routine surgery for colon cancer can be improved with the hope that it will save more lives and that molecular markers can help select patients for chemotherapy and this is being applied in ongoing studies.

He has taken part in many national and international clinical trials and is currently involved in 23 UK trials attempting to improve treatments for bowel cancer patients.

He leads the pathology component within the United Kingdom Bowel Cancer Screening Programme.

GUEST SPEAKERS

Professor Dushyant V Sahani



Dushyant V. Sahani, M.D., is Associate Professor of Radiology at Harvard Medical School and Director of Computed Tomography at Massachusetts General Hospital, both in Boston, Massachusetts.

Dr Sahani is a board certified radiologist and fellow trained in abdominal imaging and intervention at Massachusetts General Hospital. Imaging of the liver, biliary and pancreas has been a focus of his research and clinical work. He is currently involved in investigating tumor angiogenesis and response to novel cancer treatment methods with CT, MRI and PET.

Dr Sahani has contributed over 200 original articles and reviews to medical literature, numerous book chapters, as well as, the author of two textbooks. His work has appeared in journals such as: the New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, Clinical Gastrointestinal Radiology and Hepatology, Radiology, American Journal of Radiology, Annals of Surgery, Investigative Radiology, and European Journal of Radiology. He has delivered over 200 lectures nationally and internationally. Dr Sahani also provides medical education to residents, fellows, and HMS students. In addition, he has been a visiting professor at numerous universities in the United States and abroad. He is a reviewer for over 25 scientific journals. Dr Sahani is also a fellow member of all leading radiology societies including: ACR, ARRS, CMR, ESGR, NERRS, RSNA, SCBT/MR, and SGR. In 2005 and 2007, he earned a research award from the Society of Gastrointestinal Radiology, and a Hounsfield award from the Society of Computed Body Tomography and MR in 2005. He was appointed 2008-2009 "Visiting professor" of the Society of Gastrointestinal Radiology. Currently, Dr Sahani serves as a member of the Board of Directors for SCBT-MR.

Professor David Sebag-Montefiore



David Sebag-Montefiore is Professor of Clinical Oncology at the University of Leeds and St. James's Institute of Oncology. He qualified at St. Bartholomew's Hospital in London and completed his oncology training at Middlesex, Mount Vernon and St. Bartholomew's Hospital before taking up his Consultant post at Cookridge Hospital in Leeds. His research interests include gastrointestinal cancer with a focus on radiotherapy and chemoradiation in rectal and anal cancer. He is a member of the NCRI colorectal study group and anorectal subgroup, CTRad workstream 3 and is a Vice-Chair of Cancer Research UK's Clinical and Translational Awards and Advisory Committee (CTAAC). He has led or co-led large phase III trials in anal and rectal cancer including the MRC CR07, ACT 2 and ARISTOTLE trials.

Dr Neil Segal



Dr. Segal, MD, PhD, is a medical oncologist in the Gastrointestinal Oncology Service, and the Immunotherapy Clinical Service at Memorial Sloan-Kettering Cancer Center, New York. He specializes in the treatment of patients with Colorectal Cancer. His research interests focus on the development of new therapies. In particular, he investigates innovative ways to augment the immune system to target tumors. He is currently Principal Investigator on several clinical trials, including beta-glucan therapy, PD/L-1 blockade and CD137 augmentation. He is a Member of Journal of Surgical Oncology Editorial Board in the Medical section and a Member of the GI steering Committee Colon Task Force.

Dr Ricky Sharma



Ricky Sharma graduated in medicine from the University of Cambridge. He trained in internal medicine in Cambridge, Glasgow and Leicester and then in medical oncology and radiation oncology in Leicester and the Royal Marsden Hospital, London, UK. In addition to board certification in oncology, Dr Sharma has a PhD on DNA damage and is a member by examination of the Royal College of Physicians and the Royal College of Radiologists.

Dr Sharma is currently Clinical Lead for the Thames Valley Cancer Research Network, HEFCE Clinical Senior Lecturer at the University of Oxford, a Laboratory Group Leader at the Gray Institute for Radiation Oncology & Biology and an Honorary Consultant in Clinical Oncology at the Oxford University Hospitals. He is also a Senior Research Fellow at Harris Manchester College, Oxford and Chair of the Cancer Teaching Committee of the University of Oxford.

The Sharma group's laboratory research is focussed on understanding DNA damage repair in malignancies of the upper and lower gastrointestinal tract. He is chief investigator for clinical trials of novel combinations of radiotherapy and chemotherapy. Dr Sharma is an international authority on the multi-modality treatment of liver metastases.



SOUTHERN SYMPOSIUM ON FOREGUT CANCERS

CORK 2012

ORGANISING COMMITTEE

Mr Criostoir O'Suilleabhain, Mercy University Hospital, Cork

Dr Derek Power, Mercy University Hospital, Cork

Dr Brian Bird, Bon Secours Hospital, Cork

Dr Martin Buckley, Mercy University Hospital, Cork

Professor Michael Maher, Cork University Hospital, Cork

Dr Peter McEneaney, Mercy University Hospital, Cork

Dr Aileen Flavin, Cork University Hospital, Cork

Dr Bill Bennett, Cork University Hospital, Cork

Dr Domhnall O'Halloran, Cork University Hospital, Cork

Ms Erica Mulvihill, Mercy University Hospital, Cork

Ms Peggy O'Keefe, Mercy University Hospital, Cork

Sponsored by

AMGEN



NOVARTIS
ONCOLOGY



Pfizer Oncology

IPSEN
Innovation for patient care

SIRTeX

Johnson & Johnson
MEDICAL

Merck Serono
Living science, transforming lives

COVIDIEN
positive results for life

Genomic Health
LIFE CHANGING